Tuesday, April 01, 2014 3:41:46 PM
Expand Genome Sequence Database for Pathogen Identification
Baltimore, Md. — April 1, 2014. Researchers at the Institute for Genome Sciences at the University
of Maryland School of Medicine have been awarded a research program contract from the U.S.
Food and Drug Administration (FDA) to sequence, assemble, and annotate a population of bacterial
pathogens using two high-throughput sequencing (HTS) technologies in support of the expansion of
a vetted public reference database.
The continued development of HTS technologies for accurate identification of microorganisms for
diagnostic use will have significant impact on human healthcare, biothreat response, food safety,
and other areas. Developing a comprehensive, curated database of microbial genome sequences and
associated metadata will serve as a valuable reference to evaluate and assess HTS-based diagnostic
devices. Leading the sequencing and analysis phases of the project, the Genomics Resource Center
(GRC) at the Institute is a cutting-edge genomic sequencing and analysis center with a long history
of high-quality microbial genomics research that has sequenced and analyzed more than 5,000
microbial genome sequences in just the past five years.
The genome sequencing will use two HTS platforms, Illumina and Pacific Biosciences, and
multiple genome assembler software packages and assembly QA/QC pipelines to assemble and
validate the resulting draft genome sequences. By using two complementary sequencing platforms,
GRC researchers will be able to cross-validate consensus sequences to generate the highest possible
genome sequence accuracy. The comprehensive, curated database to which these annotated genome
sequences will be added will enable high confidence confirmation of in vitro microbial pathogen
identification. This database will be accessible through the collection of the National Center for
Biotechnology Information (NCBI)’s public domain databases. The combination of genomic data
and metadata will help to advance the goal of developing HTS-based in vitro diagnostics and the
assessment of their potential.
The GRC was formed to serve the global genomics and bioinformatics communities, and its
reputation is built on both its deep history in sequencing, genomics and analysis, and its end-to-end
service level from initial project consultation through publication. The GRC is led by Luke Tallon,
scientific director and founding leader of the GRC, and Lisa Sadzewicz, administrator director of
the facility. “We are excited to contribute our genome sequencing and analysis expertise to this
important project with the FDA,” says Tallon.
“This database will be an important reference for the scientific and medical diagnostic
communities,” says Claire Fraser, PhD, Director of the Institute for Genome Sciences. “We have
worked with federal agencies and global scientific partners to sequence and analyze an extensive
population of bacterial pathogens since our Institute launched in 2007 and are pleased to develop
this reference database with the FDA.”
“The Institute for Genome Sciences is truly unique to an academic medical university because it
houses cutting-edge sequencing technologies overseen by internationally renowned experts in the
field who are deeply engaged in the research enterprise,” says E. Albert Reece, MD, PhD, MBA,
vice president for medical affairs at the University of Maryland, and John Z. and Akiko K. Bowers
distinguished professor and dean of the University of Maryland School of Medicine. “This award
recognizes the strength of the University of Maryland School of Medicine’s genomics program,
which will make significant contributions to better identifying and, ultimately, treating infectious
diseases.”
About the University of Maryland School of Medicine
Established in 1807, the University of Maryland School of Medicine is the first public medical
school in the United States, the first to institute a residency-training program. The School of
Medicine was the founding school of the University of Maryland and today is an integral part of the
11-campus University System of Maryland. On the University of Maryland’s Baltimore campus, the
School of Medicine serves as the anchor for a large academic health center which aims to provide
the best medical education, conduct the most innovative biomedical research and provide the best
patient care and community service to Maryland and beyond. www.medschool.umaryland.edu
About the Institute for Genome Sciences
The Institute for Genome Sciences (IGS) is an international research center within the University of
Maryland School of Medicine. Comprised of an interdisciplinary, multidepartment team of
investigators, the Institute uses the powerful tools of genomics and bioinformatics to understand
genome function in health and disease, to study molecular and cellular networks in a variety of
model systems, and to generate data and bioinformatics resources of value to the international
scientific community. www.igs.umaryland.edu
#### http://www.igs.umaryland.edu/labs/grc/files/2014/04/FDA-Announcement-3-26-14_final.pdf
Recent PACB News
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases • PR Newswire (US) • 05/15/2024 01:45:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:33:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:21:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:12:15 PM
- PacBio Announces First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:05:00 PM
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM